GSK Buys Pulmonary Hypertension Drug in $950M Deal; Alkermes CEO Retires; Novo Expands Oral Peptides

GSK has acquired a pulmonary hypertension drug from 35Pharma for $950 million, enhancing its portfolio in rare diseases. Meanwhile, Alkermes CEO Richard Pops is set to retire, signaling leadership changes in biotech. Novo Nordisk is also increasing its focus on oral peptides, reflecting a broader shift towards easier administration routes for biologics. Watch for further drug development updates and leadership transitions in these companies.